Nifedipine does not blunt the aldosterone and cardiovascular response to angiotensin II and potassium infusion in hypertensive patients

L. Terzoli, G. Leonetti, R. Pedretti, R. Bragato, L. Sampieri, M. Fruscio, L. Boselli, A. Zanchetti

Research output: Contribution to journalArticlepeer-review


The antihypertensive response of calcium antagonists of the dihydropyridine series, although accompanied by a significant increase in plasma renin activity (PRA), is generally not associated with a comparably significant rise in plasma aldosterone (PA). This has been suggested to be due to the adrenal glomerular cell responsiveness being dependent on calcium entry. To investigate this hypothesis, angiotensin II (All; 0.15, 0.375, and 0.750 μg/min, each step for 20 min) and KCl (30 mmol/50 min) were infused on separate days in 11 hypertensive patients kept at a constant daily intake of 100 mmol sodium and 40 mmol potassium, before and after 1 week of nifedipine treatment (20 mg b.i.d.). Supine blood pressure (BP) was significantly (p <0.01 -p <0.001) reduced after nifedipine treatment; supine PRA increased significantly (p <0.01), while PA did not change significantly. No change in plasma potassium level was seen during nifedipine treatment. The dose-dependent mean BP rises induced by All were slightly blunted during nifedipine treatment, whereas the PRA decreases and the PA rises after the peak infusion were not significantly different before and during nifedipine administration. Potassium infusion had no significant effect on BP, and caused a significant and similar rise in PA before and during nifedipine administration, while PRA decrease was more pronounced after nifedipine treatment. As previously shown in normotensive subjects, and also in hypertensive patients, aldosterone responses to two major stimulants, such as All and potassium, do not appear to be blunted by treatment with a calcium antagonist.

Original languageEnglish
Pages (from-to)317-320
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Issue number3
Publication statusPublished - 1988


  • Aldosterone responsiveness
  • Angiotensin II infusion
  • Ca<sup>2+</sup> antagonist
  • K<sup>+</sup> infusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology


Dive into the research topics of 'Nifedipine does not blunt the aldosterone and cardiovascular response to angiotensin II and potassium infusion in hypertensive patients'. Together they form a unique fingerprint.

Cite this